AirNexis Therapeutics
AirNexis Therapeutics develops medicines for pulmonary diseases, led by the investigational COPD candidate AN01.
$200MSeries A
Role not disclosedSO
SR One
Activity from announced rounds
Activity in this selectionUnited States · Jan 31, 2026 · Jan 1, 2026
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $250M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionPoplar Therapeutics
Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions
$50MSeries A
Role not disclosed